经济观察网 新开源（300109）近期在资产重组、高管变动、财务业绩及股东结构方面出现一系列动 态。公司重大资产重组方案可能出现重大调整，涉及收购标的博爱新开源生物科技有限公司的股权结构 变更，原投资方因资金问题未能实缴注册资本，已引入新股东接手部分义务。深交所曾就此次重组的高 溢价问题发出问询函，要求补充披露标的资产估值及核心竞争力等细节。 高管变动 截至2026年1月31日，新开源股东户数为18,295户，较1月20日减少1,205户，环比下降6.18%。同期股价 小幅上涨，融资余额增加。 以上内容基于公开资料整理，不构成投资建议。 2025年前三季度公司主营收入9.51亿元，同比下降14.36%；归母净利润2.01亿元，同比下降35.39%。单 季度第三季度收入及利润均出现下滑，毛利率为43.58%。 股东人数情况 高级副总经理于江涛因工作调动不再担任该职务，但继续担任公司非独立董事。此次变动可能影响公司 管理结构，于江涛2024年薪酬为59.60万元，在董事及高管中排名居中。 业绩经营情况 ...

- The report does not contain any quantitative models or factors for analysis [1][2][3][4]

- The report does not contain any quantitative models or factors for analysis[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]

Group 1 - New Source (stock code: 300109.SZ) held an investor meeting on February 6, 2023, in Shanghai, attended by 37 institutions including Shenwan Hongyuan and Everbright Securities [2][15] - Since 2026, 18 A-share listed companies from Henan have received institutional research, with Xiangyu Medical leading with 208 institutions participating [16][23] - The demand for core products, particularly PVP series products and their applications in emerging fields, was a major focus during the meeting [3][17] Group 2 - New Source is a leading high-tech enterprise in the research, development, and production of PVP series products, with a total domestic production capacity of 57,000 tons per year, accounting for 53% of global capacity and a 34% global market share [18] - PVP is widely used in various sectors, including daily chemicals, pharmaceuticals, food and beverage, materials, and new energy, with significant applications in solid-state batteries and photovoltaic cells [18][4] - The company expects to sell approximately 4,000 tons of PVP in the new energy sector by 2025, with a projected 20% increase in 2026 [4][19] Group 3 - The price of PVP products has been affected by rising raw material costs due to the European energy crisis and the Russia-Ukraine conflict, leading to increased prices and profit margins, which are not expected to be sustainable [5][19] - Another core product, Euriz (PVM/MA), has a high single-ton price with a gross margin of approximately 60%-70%, with expected shipments of about 900 tons in 2025 [20] - New Source has made strategic investments in five cell and gene therapy companies to enhance its competitive edge in the precision medical field [20][21] Group 4 - New Source's invested companies are progressing well, with one product entering NDA approval and several others in clinical stages, indicating potential for future growth and IPO opportunities [21] - The company's governance structure is relatively decentralized, with major shareholders expressing confidence in the long-term development of the company and intentions to increase their holdings [21][22] - Institutional interest in Henan-listed companies reflects recognition of their investment value, with many companies being leaders in their respective sectors [25]

证券日报网2月9日讯 ，新开源（300109）在接受调研者提问时表示，公司高度重视股东沟通与投资者 关系管理，前期已就公司经营发展、治理安排等事项与前十大股东进行充分沟通，各方已形成高度一致 意见。公司将全力以赴抓好生产经营，持续提升经营质量与核心竞争力，切实为全体股东创造长期价 值。目前公司股权结构相对分散，公司控股股东、实际控制人及其一致行动人始终看好公司长期发展前 景，具备增持意向。未来在合规前提下、择机通过处置部分个人体外资产筹措资金，用于增持公司股 份，进一步优化股权结构、稳定控制权，彰显对公司未来发展的坚定信心。 ...

Core Viewpoint - The company is actively engaging with investors and stakeholders to discuss its product developments, market strategies, and future growth prospects, particularly in the PVP product line and high-margin offerings like Euriz. Group 1: PVP Product Insights - The prices of PVP series products are expected to gradually recover in 2026 after a period of high margins due to the European energy crisis and the Russia-Ukraine conflict, which had previously inflated raw material costs [3] - The company anticipates that PVP product sales will enter an upward trend based on market demand and supply dynamics [3] Group 2: New Energy and Photovoltaic Applications - In the new energy battery sector, PVP is utilized as a dispersant for carbon nanotubes, with sales projected to reach approximately 4,000 tons in 2025, expecting a 20% increase in 2026 [4] - In the photovoltaic sector, PVP serves as a key surfactant/dispersant for spherical silver powder, which is crucial for silver paste printing performance and battery efficiency, with 2025 shipments estimated at 200 tons and continued growth expected in 2026 [4] Group 3: Euriz Product Advantages - Euriz (ethylene-vinyl ether/maleic anhydride copolymer) is a high-value product with a high price per ton and a gross margin of approximately 60-70%, with an expected shipment volume of around 900 tons in 2025 [5] - The company is the only manufacturer globally using a non-benzene process for Euriz production, creating a significant technical barrier and is actively seeking partnerships to enhance market presence [5] Group 4: Shareholder Communication and Equity Structure - The company emphasizes effective communication with shareholders and has reached consensus with its top ten shareholders on operational and governance matters [6] - The major shareholder plans to increase their stake in the company by liquidating some personal assets, aiming to optimize the equity structure and stabilize control [6] Group 5: Medical Sector Developments - The company has invested in five cell and gene therapy enterprises, with several products progressing well in their development stages, including one product entering NDA approval and others in clinical trials [7] - Some of these enterprises are positioned to potentially achieve NDA approval and initiate IPOs, with the company collaborating closely with them for market promotion and commercialization [7] Group 6: Strategic Transformation Goals - The company is transitioning from a capacity-led approach to a focus on technology and service leadership, with plans to establish itself as a global leader in functional chemicals by 2025-2027 [8]

Group 1: Investor Relations Activity - The investor relations activity included a meeting with analysts and representatives from various financial institutions [2][3] - Key participants included analysts from New Fortune Magazine, Shenwan Hongyuan Securities, and several private equity funds [2][3] Group 2: Company Overview and Product Insights - The company is focused on PVP series products, which experienced price increases due to the European energy crisis and the Russia-Ukraine conflict, but is expected to stabilize in 2026 [3][4] - In 2025, the company sold approximately 4,000 tons of PVP products in the new energy sector, with a projected 20% increase in 2026 [4] - The company also sold about 200 tons of PVP products in the photovoltaic industry in 2025, with expected growth in 2026 [4] Group 3: Product Development and Strategic Goals - The company is transitioning from "capacity leading" to "technology leading + service leading" as part of its strategic upgrade plan initiated in 2025 [4][5] - The company is the only manufacturer using a non-benzene process for producing its products, which provides a competitive edge [5] Group 4: Shareholder Communication and Equity Structure - The company emphasizes shareholder communication and has engaged with its top ten shareholders regarding operational and governance matters [6][7] - The controlling shareholder and their associates are optimistic about the company's long-term prospects and have intentions to increase their shareholding [7] Group 5: Medical Sector Investments - The company has strategically invested in five biotechnology firms focusing on innovative drug development, with several products advancing through regulatory stages [6][7] - One product is in the NDA approval stage, two are in Phase II clinical trials, and several others have received IND approvals in China and the U.S. [7]

证券日报网讯 2月5日，新开源发布公告称，公司董事会近日收到非独立董事于江涛先生提交的书面辞 职报告，因公司治理结构调整，于江涛先生申请辞去公司第五届董事会董事、高级副总经理职务，辞职 报告自送达董事会之日起生效，辞职后继续担任公司其他职务。公司于2026年2月4日召开职工代表大 会，经职工代表大会表决通过，同意选举于江涛先生为公司第五届董事会职工代表董事，任期自本次公 司职工代表大会选举决议生效之日起至公司第五届董事会任期届满之日止。 （编辑 袁冠琳） ...

证券代码：300109 证券简称：新开源 公告编号：2026-018 博爱新开源医疗科技集团股份有限公司 关于非独立董事、高管辞职暨选举职工代表董事的公告 本公司及其董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、非独立董事辞职情况 博爱新开源医疗科技集团股份有限公司（以下简称"公司"）董事会近日收 到公司非独立董事于江涛先生提交的书面辞职报告，因公司治理结构调整，于江 涛先生申请辞去公司第五届董事会董事、高级副总经理职务，辞职报告自送达董 事会之日起生效，辞职后继续担任公司其他职务。 于江涛先生原定任职时间为 2023 年 3 月 23 日至 2026 年 3 月 22 日。于江涛 先生辞职不会导致公司董事会成员低于法定人数，不会影响公司的正常生产经 营，不会影响相关工作的正常进行。 截至本公告披露日，于江涛先生持有公司股票 395,000 股，不存在应履行而 未履行的承诺事项。 于江涛先生将继续严格按照《上市公司股东减持股份管理暂行办法》《深圳 证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减持 股份》等相关法律法规的规定管理其所持股份。 二 ...

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Chip Design Theme Index (950162) rose by 2.19% as of February 3, 2026, indicating strong market performance in the chip design sector [1] - The E Fund Sci-Tech Chip Design ETF (589030) increased by 1.46%, with a trading volume of 66.14 million yuan and a turnover rate of 13.6%, reflecting active market participation [1] - The E Fund Sci-Tech Chip Design ETF has seen continuous net inflows over the past four days, with a peak single-day net inflow of 82.71 million yuan, totaling 172 million yuan [1] Group 2 - The semiconductor industry is entering a new upcycle driven by AI applications, with a recovery starting in January 2024 and a peak expected in August 2024 [2] - The overall upward trend in the semiconductor sector is confirmed, with AI application deepening and rising storage chip prices as core drivers [2] - The E Fund Sci-Tech Chip Design ETF closely tracks the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Chip Design Theme Index, which includes listed companies involved in chip design [2]